Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). (Q33813191)

29 July 2017

1 reference

title

Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). (English)

1 reference

29 July 2017

K D Rainsford

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

American Journal of Medicine

29 July 2017

published in

1 reference

29 July 2017

volume

107

1 reference

29 July 2017

issue

6A

1 reference

29 July 2017

page(s)

27S-35S; discussion 35S-36S

1 reference

Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

The treatment of osteoarthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Review article: COX-II inhibitors--a new generation of safer NSAIDs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

An analysis from clinico-epidemiological data of the principal adverse events from the COX-2 selective NSAID, nimesulide, with particular reference to hepatic injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Protection from gastrointestinal side-effects by azapropazone by its incorporation into a glucose-sodium acid citrate formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Relationship of gastric mucosal damage induced in pigs by antiinflammatory drugs to their effects on prostaglandin production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Classical absorption theory and the development of gastric mucosal damage associated with the non-steroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Dissolution and partition thermodynamic functions of some nonsteroidal anti-inflammatory drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

The amphiprotic character of azapropazone and its relevance to the gastric mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

hP, the component of log P controlling structure-activity relationships amongst non-steroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Interactions of Nonsteroidal Antiinflammatory Drugs with Phospholipids: Comparison between Octanol/Buffer Partition Coefficients and Chromatographic Indexes on Immobilized Artificial Membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Structure-activity relationships of non-steroid anti-inflammatory drug 1. Gastric ulcerogenic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Esterification of acidic anti-inflammatory drugs suppresses their gastrotoxicity without adversely affecting their anti-inflammatory activity in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Gastric ulcerogenicity of non-steroidal anti-inflammatory drugs in mice with mucosa sensitized by cholinomimetic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Correlation between gastric irritancy and anti-inflammatory activity of non-steroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Relationship between lipophilicity and binding to human serum albumin of arylpropionic acid non-steroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Role of surface-active phospholipids in gastric cytoprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Phosphatidylcholines as mediators of adaptive cytoprotection of the rat duodenum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Gastric mucosal barrier: barrier to hydrogen ions imparted by gastric surfactant in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Deranged hydrophobic barrier of the rat gastroduodenal mucosa after parenteral nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Biochemical pharmacology of nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

7 January 2021

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Effects of the prodrug nabumetone, and its active metabolite, 6-MNA, on human and rat gastric mucosal prostanoids and platelet function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Effects of meloxicam, compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukins 1, 6 and 8, in human and porcine explants in organ culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Can non-steroidal anti-inflammatory drugs act as metalloproteinase modulators? An in-vitro study of inhibition of collagenase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

Luminal surface hydrophobicity of canine gastric mucosa is dependent on a surface mucous gel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Morphological effects of aspirin and prostaglandin on the canine gastric mucosal surface. Analysis with a phospholipid-selective cytochemical stain

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900365-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)00365-4

1 reference

29 July 2017

1 reference